open access

Vol 77, No 1 (2009)
REVIEWS
Published online: 2008-12-19
Submitted: 2013-02-22
Get Citation

Omalizumab, recombinant humanized monoclonal antibody anti-IgE - new fields of studies on the therapeutic indications

Izabela Kupryś-Lipińska, Piotr Kuna
Pneumonol Alergol Pol 2009;77(1):43-51.

open access

Vol 77, No 1 (2009)
REVIEWS
Published online: 2008-12-19
Submitted: 2013-02-22

Abstract

Omalizumab is the monoclonal antibody against IgE, which blocks the binding of IgE to receptors on effector cells and this way blocks or decreases allergic reaction and asthma symptoms. Nowadays omalizumab is registered in the USA and European Union including Poland for treatment of patients with severe persistent, uncontrolled asthma. It is very effective in the reduction of asthma exacerbations, hospitalizations and emergency visits, it decreases intensity of symptoms and improves the quality of life. But omalizumab has more extensive action; given subcutaneously it has systemic effect. The article is the review of the studies and case reports on usage of omalizumab in new indications. Some authors’ own experiences in this field are also presented.

Abstract

Omalizumab is the monoclonal antibody against IgE, which blocks the binding of IgE to receptors on effector cells and this way blocks or decreases allergic reaction and asthma symptoms. Nowadays omalizumab is registered in the USA and European Union including Poland for treatment of patients with severe persistent, uncontrolled asthma. It is very effective in the reduction of asthma exacerbations, hospitalizations and emergency visits, it decreases intensity of symptoms and improves the quality of life. But omalizumab has more extensive action; given subcutaneously it has systemic effect. The article is the review of the studies and case reports on usage of omalizumab in new indications. Some authors’ own experiences in this field are also presented.
Get Citation

Keywords

omalizumab; atopic diseases; allergic rhinitis; atopic dermatitis; urticaria

About this article
Title

Omalizumab, recombinant humanized monoclonal antibody anti-IgE - new fields of studies on the therapeutic indications

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 1 (2009)

Pages

43-51

Published online

2008-12-19

Bibliographic record

Pneumonol Alergol Pol 2009;77(1):43-51.

Keywords

omalizumab
atopic diseases
allergic rhinitis
atopic dermatitis
urticaria

Authors

Izabela Kupryś-Lipińska
Piotr Kuna

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl